🔷 Updated March 2026

Psoriatic Arthritis
Clinical Trials

IL-17 inhibitors, IL-23 blockers, JAK inhibitors, and novel biologics are actively recruiting PsA patients with skin and joint disease. Search below and get a plain-English summary of any study.

200+
PsA trials currently recruiting
$0
Cost to participants in most trials
Phase 3
Most active trials are late-stage
Live from ClinicalTrials.gov
Find PsA Trials Near You

Who Is Eligible for Psoriatic Arthritis Clinical Trials?

Most PsA trials require a confirmed diagnosis per CASPAR criteria with active joint and/or skin disease. Common requirements include a minimum number of tender and swollen joints, active psoriatic skin lesions (at least one plaque of a defined size), and prior exposure to at least one conventional DMARD such as methotrexate. Many trials now recruit specifically for patients who have failed one or more biologics — particularly TNF inhibitors.

What Treatments Are Being Tested?

Drug ClassHow It WorksWho It Is For
IL-17A/F inhibitors Block the IL-17 pathway driving both skin and joint inflammation in PsA Active PsA with skin involvement, prior DMARD failure
IL-23 inhibitors Target the p19 subunit of IL-23, a key driver of psoriatic inflammation Moderate-to-severe PsA, often biologic-naive or experienced
Selective JAK inhibitors Block intracellular signaling with improved selectivity profiles over first-generation agents PsA patients who failed biologics
TYK2 inhibitors Novel oral pathway targeting TYK2 kinase involved in IL-23 and IFN signaling Active PsA, often biologic-naive
Biosimilars FDA-approved copies of approved biologics at reduced cost Any PsA patient eligible for the reference biologic

What to Expect as a Trial Participant

Most PsA trials run 24-52 weeks with a primary endpoint focused on joint response (ACR20) and skin response (PASI). Visits are typically every 4-8 weeks with joint assessments, skin evaluations, and labs at each visit.

Related Tool
CASPAR Criteria for Psoriatic Arthritis
Check whether your symptoms meet the formal CASPAR criteria for PsA — the same criteria trial coordinators use to confirm eligibility.
Open Calculator

Frequently Asked Questions

Adults with a confirmed PsA diagnosis and active joint or skin disease are the core population. Most trials require a minimum number of swollen and tender joints plus active psoriasis. Prior methotrexate use is often required. Some trials enroll biologic-naive patients; others specifically want patients who have failed TNF inhibitors or IL-17/IL-23 agents.
Most PsA trials require at least one qualifying psoriatic plaque — typically 2cm or larger. However, some trials focused purely on joint disease have lower skin requirements. The trial coordinator will assess your current skin involvement at screening.
Yes. Many trials are specifically designed for biologic-experienced patients. Having tried and failed TNF inhibitors makes you eligible for trials of IL-17, IL-23, JAK, and TYK2 agents — all of which use different mechanisms.
Most PsA trials allow you to continue stable background methotrexate. Some are add-on studies — the investigational drug is added to your existing therapy. The trial team will specify exactly what is required at screening.
Phase 3 trials have completed earlier safety phases and are typically testing new agents against approved treatments. All trials require IRB approval and FDA oversight. You can withdraw at any time.
Joint response (ACR20/50/70), skin response (PASI 75/90/100), enthesitis resolution, dactylitis resolution, physical function (HAQ-DI), and quality of life. Some trials also use imaging endpoints to assess bone erosion progression.

Other Rheumatology Trials

Trial data sourced live from ClinicalTrials.gov. Content reviewed by Mahiar Rabie, MS, MD. This page is for informational purposes only and does not constitute medical advice. Eligibility for any specific trial must be confirmed with the trial coordinator.